EHRA Premium Access

Strategies for screening and identifying which patients to protect with the WCD.

Presentation

About the speaker

Professor Joachim Ehrlich

St. Josefs-Hospital, Wiesbaden (Germany)
2 presentations
0 follower

4 more presentations in this session

Introduction - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Doctor G. Botto (Garbagnate Milanese, IT)

Thumbnail

Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?

Speaker: Doctor S. Reif (Munich, DE)

Thumbnail

The impact of the WCD for patients who choose to wear it.

Speaker: Professor D. Scherr (Graz, AT)

Thumbnail

Panel discussion and summary - Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death.

Speaker: Doctor O. Piot (Saint Denis, FR)

Thumbnail

Access the full session

Who should receive the Wearable Cardioverter Defibrillator (WCD)? Evidence and risk stratification for prevention of sudden cardiac death

Speakers: Professor J. Ehrlich, Doctor G. Botto, Doctor S. Reif, Professor D. Scherr, Doctor O. Piot
Thumbnail

About the event

Image

EHRA 2019

17 March - 19 March 2019

Sessions Presentations

Related content

Open Access

Challenges in SCD risk stratification.

28 August 2021

ESC Premium Access

Wearable devices and their role in sub-clinical arrhythmia detection.

28 August 2021

This platform is supported by

logo Novo Nordisk